title: A mesoporous silica nanoparticulate/β-TCP/BG composite drug delivery system for osteoarticular tuberculosis therapy.
abstract: A composite scaffold drug delivery system (CS-DDS) for osteoarticular tuberculosis therapy has been prepared by loading bi-component drugs into a mesoporous silica nanoparticles (MSNs)-coated porous β-TCP scaffold, which was followed by an additional bioactive glass coating. Such a CS-DDS showed high performances in the local and extremely sustained delivery of the bi-component antitubercular drugs and excellent biocompatibility. N(2) sorption isotherms indicated greatly increased surface area of the composites compared to pure β-TCP scaffold, and the mesopores were around 2.6 nm which were large enough to encapsulate drugs such as isoniazide and rifampicin. The in vitro and in vivo release tests demonstrated extra sustained co-release profiles of rifampicin and isoniazide from such a CS-DDS, and both drug concentrations kept higher than their effective values to kill mycobacterium tuberculosis for as long as 42 days. The hepatic and renal function tests indicated that the CS-DDS had neglectable long-term lesions to liver and kidney.
authors.affiliation: State Key Laboratory of High Performance Ceramics and Superfine Microstructure, Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Ding-Xi Road, Shanghai, 200050, PR China.
authors.forename: Min
authors.initials: M
authors.lastname: Zhu
authors.forename: Huixue
authors.initials: H
authors.lastname: Wang
authors.forename: Jiyong
authors.initials: J
authors.lastname: Liu
authors.forename: Hailong
authors.initials: H
authors.lastname: He
authors.forename: Xuguo
authors.initials: X
authors.lastname: Hua
authors.forename: Qianjun
authors.initials: Q
authors.lastname: He
authors.forename: Lingxia
authors.initials: L
authors.lastname: Zhang
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Ye
authors.forename: Jianlin
authors.initials: J
authors.lastname: Shi
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001672:Biocompatible Materials; D002130:Calcium Phosphates / Q000737:chemistry*; D002460:Cell Line; D016503:Drug Delivery Systems / Q000009:adverse effects / Q000379:methods*; D007538:Isoniazid / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000472:pathogenicity; D053761:Nanocomposites / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D016062:Porosity; D011817:Rabbits; D012293:Rifampin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D012822:Silicon Dioxide / Q000737:chemistry*
chemical_list: D000995:Antitubercular Agents; D001672:Biocompatible Materials; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate; D012822:Silicon Dioxide; D007538:Isoniazid; D012293:Rifampin